BUZZ-U.S. Stocks on the Move-Capital Product, Infinity, Tetraphase

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning Call newsletter, http://link.reuters.com/nex49s)

U.S. stock index futures rose on Wednesday, on hopes a resolution would be reached between Ukraine and Russia and ahead of the latest batch of data which could provide insight on the health of the economy. Dow Jones industrial average futures were up 0.36 percent at 17,115, S&P 500 futures were up 0.33 percent at 2,006.25 and Nasdaq 100 futures were up 0.31 percent at 4,104.5.

** INFINITY PHARMACEUTICALS INC (NasdaqGS: INFI - news) , Tuesday close $10.92, +42.40 pct premarket

The drug developer entered into a deal with AbbVie Inc (NYSE: ABBV - news) to develop cancer drug duvelisib, codenamed IPI-145, for which it will get upfront payment of $275 million and up to $530 million in milestone payments.

Infinity also signed an agreement with Roche Holding AG (Other OTC: RHHBF - news) to test Roche's cancer drug Gazyva, or obinutuzumab, in combination with its experimental cancer drugs.

** CAPITAL PRODUCT PARTNERS LP, Tuesday close $10.96, -6.02 pct premarket

The shipping company said on Tuesday that it plans to offer 15 million common units. The offering represented nearly 14 pct of the company's outstanding shares as of Tuesday. The company said it planned to use proceeds to part fund purchase of two product carriers and buy back units worth $60 million from Capital Maritime & Trading Corp.

** ELLINGTON FINANCIAL LLC (NYSE: EFC - news) , Tuesday close $24.6, -3.50 pct premarket

The specialty finance company announced a public offering of 8 million common shares, or 31.5 pct of total outstanding shares and planned to use proceeds to acquire assets.

The company had 25.44 million shares outstanding on Aug. 1.

** TETRAPHASE PHARMACEUTICALS INC (NasdaqGS: TTPH - news) , Tuesday close $13.08, +11 pct after market

The drugmaker's experimental drug to treat complicated urinary tract infection was successful in late-stage study. The drug in two doses was found more effective than levofloxacin, an antibiotic usually prescribed for the condition.

JMP Securities raised its price target on stock to $20 from $16. The median price target on stock is $20.50.

** TOLL BROTHERS INC (NYSE: TOL - news) , Tuesday close $35.63, +0.20 pct premarket

the largest U.S. luxury homebuilder's quarterly income more than doubled as it sold more homes at higher prices.

** SHANDA GAMES LTD, Tuesday close $6.28, -3.98 pct premarket

Private equity firms Carlyle Group LP and Fountainvest Partners have pulled out of a consortium backing a $1.9 billion bid to buy the online games developer.

** HELEN OF TROY LTD, Tuesday close $59.15, -8.72 pct premarket

The personal care products and houseware maker lowered its full-year profit and revenue forecast, citing recent retail weakness. "In our personal care business, the multi-year downward trend has accelerated recently, particularly in the more commoditized parts of our appliance business," Chief Executive Julien Mininberg said.

** GUIDEWIRE SOFTWARE INC (NYSE: GWRE - news) , Tuesday close $45.82, -6.92 pct premarket

The company, which provides software for property and casualty insurers, reported better-than-expected fourth quarter profit and revenue as license revenue jumped 34 percent. "New licenses included key Tier 1 wins, full suite sales and expanded relationships with existing customers ... on our newer products," Chief Executive Marcus Ryu said.

** GOOGLE INC (Xetra: A0B7FY - news) , Tuesday close $588.63, +0.24 pct premarket

The Internet giant said a research team led by physicist John Martinis from the University of California Santa Barbara will join the company to start a project to build new quantum information processors based on superconducting electronics.

** BAIDU INC (Xetra: A0F5DE - news) , Tuesday close $224.8, +1.11 pct premarket

The company launched on Wednesday a service that helps retailers advertise on the smartphones of nearby users as China's dominant search engine company expands its location-based technology to drive growth.

** GENERAL ELECTRIC CO, Tuesday close $25.85, +0.15 pct premarket

The company's healthcare unit last week won U.S. Food and Drug Administration approval for its mammography device that produces three-dimensional images to detect breast cancer.

** CONCUR TECHNOLOGIES INC (NasdaqGS: CNQR - news) , Tuesday close $100.95, +10.94 pct premarket

The travel management and expense software maker is exploring a sale of the company and has approached Oracle Corp and Germany's SAP SE (NYSE: SAP - news) , Bloomberg reported, citing people with knowledge of the matter.

** PACIFIC GAS AND ELECTRIC CO, Tuesday close $47.29, +0.30 pct premarket

The California Public Utilities Commission on Tuesday levied penalties of a record $1.4 billion on PG&E, stemming from the deadly 2010 San Bruno natural gas pipeline rupture and fire near San Francisco.

** JPMORGAN CHASE & CO (Xetra: 850628 - news) , Tuesday close $59.67, +0.70 pct premarket

** BANK OF AMERICA CORP, Tuesday close $16.27, -0.06 pct premarket

JPMorgan Chase is in talks to sell its oil-supply agreement with a Carlyle Group-owned Philadelphia Energy Solutions Philadelphia refinery to Bank of America, the Wall Street Journal reported Tuesday, citing people familiar with the matter.

** VODAFONE GROUP PLC, Tuesday close $34.32, +1.34 pct premarket

A Nikkei report suggested the British mobile operator may become a takeover target for Japanese telecoms firm SoftBank Corp (Xetra: 891624 - news) .

** SANOFI SA, Tuesday close $54.97, +0.96 pct premarket

The French drugmaker, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 percent in a large final clinical trial.

** TEVA PHARMACEUTICAL INDUSTRIES LTD, Tuesday close $52.14, +0.46 pct premarket

** ASTRAZENECA PLC (NYSE: AZN - news) , Tuesday close $74.64, +0.95 pct premarket

The Israel-based company said Britain's High Court had handed down a positive judgment regarding its case against a patent for AstraZeneca's Symbicort lung drug. (Compiled by Rohit T.K. in Bangalore; Editing by Joyjeet Das)